CD247 and diffuse large B-cell lymphoma: The intracellular regions consist of CD3ζ and a co-stimulatory 4-1BB domain, making it a second-generation CAR.72,73 The second-generation CAR T-cell therapy to gain FDA approval was axicabtagene ciloleucel (axi-cel) for diffuse large B-cell lymphoma (DLBCL).